Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Dr Reddys Laboratories Ltd RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NYSE:RDY)

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Business Wire February 20, 2026

Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

Business Wire January 14, 2026

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Business Wire December 2, 2025

Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025

Business Wire October 22, 2025

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

PR Newswire August 25, 2025

Dr. Reddy's Q1FY26 Financial Results

Business Wire July 23, 2025

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

GlobeNewswire June 5, 2025

Dr. Reddy's Q4 & Full Year FY25 Financial Results

Business Wire May 9, 2025

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

PR Newswire March 27, 2025

Opinion & Analysis (NYSE:RDY)

No current opinion is available.

Bullboard Posts (NYSE:RDY)

Big news with COYA!

https://youtu.be/SEh4ra1xKtM?si=mMoM3EDtm0zzlUhb
BryceCanada - January 4, 2024

Drill program?

Looks like an internet project...anyone know if they have a drill program going?  
unclescrooge07 - January 14, 2021

Fast mover

This stock has the potential to move very quickly they have a very low share count trdeable and each PP carries a one dollar warrant...
GMAN66 - January 12, 2021

RDY is live

Good first day of trading! Close at .49 which is 11 cents under the pp at .60...these guys have done a great job getting thia together in...
GMAN66 - January 12, 2021

Looks like it is out ! Congrats to all -Quick question

TDAmeritrade is showing RDY.CN in my account reflecting the correct number of shares post split . I am a customer of TD in USA, it use to...
ctblizzard - January 12, 2021

RE:Starts trading tomorrow

Thank you!
ctblizzard - January 11, 2021